CZ292631B6 - Deriváty pyridonkarboxylové kyseliny, protinádorové a farmakologické prostředky je obsahující - Google Patents

Deriváty pyridonkarboxylové kyseliny, protinádorové a farmakologické prostředky je obsahující Download PDF

Info

Publication number
CZ292631B6
CZ292631B6 CZ19963643A CZ364396A CZ292631B6 CZ 292631 B6 CZ292631 B6 CZ 292631B6 CZ 19963643 A CZ19963643 A CZ 19963643A CZ 364396 A CZ364396 A CZ 364396A CZ 292631 B6 CZ292631 B6 CZ 292631B6
Authority
CZ
Czechia
Prior art keywords
group
halogen
substituted
hydrogen atom
carbon atoms
Prior art date
Application number
CZ19963643A
Other languages
Czech (cs)
English (en)
Other versions
CZ364396A3 (en
Inventor
Kyoji Tomita
Katsumi Chiba
Shigeki Kashimoto
Koh-Ichiro Shibamori
Yasunori Tsuzuki
Original Assignee
Dainippon Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co., Ltd. filed Critical Dainippon Pharmaceutical Co., Ltd.
Publication of CZ364396A3 publication Critical patent/CZ364396A3/cs
Publication of CZ292631B6 publication Critical patent/CZ292631B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CZ19963643A 1994-06-14 1995-06-06 Deriváty pyridonkarboxylové kyseliny, protinádorové a farmakologické prostředky je obsahující CZ292631B6 (cs)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP15657894 1994-06-14
JP19792194 1994-07-28
JP30691494 1994-11-15
JP33995694 1994-12-28
JP8170595 1995-03-13

Publications (2)

Publication Number Publication Date
CZ364396A3 CZ364396A3 (en) 1997-06-11
CZ292631B6 true CZ292631B6 (cs) 2003-11-12

Family

ID=27524935

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ19963643A CZ292631B6 (cs) 1994-06-14 1995-06-06 Deriváty pyridonkarboxylové kyseliny, protinádorové a farmakologické prostředky je obsahující

Country Status (27)

Country Link
US (1) US5817669A (instruction)
EP (1) EP0787726B1 (instruction)
JP (1) JP3391796B2 (instruction)
KR (1) KR100350921B1 (instruction)
CN (1) CN1053668C (instruction)
AT (1) ATE209645T1 (instruction)
AU (1) AU679859B2 (instruction)
BR (1) BR9508037A (instruction)
CA (1) CA2192824C (instruction)
CZ (1) CZ292631B6 (instruction)
DE (1) DE69524251T2 (instruction)
DK (1) DK0787726T3 (instruction)
ES (1) ES2163512T3 (instruction)
FI (1) FI112485B (instruction)
HK (1) HK1000495A1 (instruction)
HU (1) HU220072B (instruction)
MX (1) MX9606331A (instruction)
NO (1) NO307255B1 (instruction)
NZ (1) NZ287139A (instruction)
PL (1) PL181867B1 (instruction)
PT (1) PT787726E (instruction)
RO (1) RO117793B1 (instruction)
RU (1) RU2151770C1 (instruction)
SI (1) SI0787726T1 (instruction)
SK (1) SK281341B6 (instruction)
TW (1) TW319769B (instruction)
WO (1) WO1995034559A1 (instruction)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504808A (ja) 2001-09-26 2005-02-17 バイエル・フアーマシユーチカルズ・コーポレーシヨン 抗糖尿病薬としての１，６−ナフチリジン誘導体
US6802423B2 (en) * 2002-02-20 2004-10-12 Trans Global Foods, Inc. Disposable food delivery apparatus
EP1610795A4 (en) * 2003-04-07 2007-10-24 Cylene Pharmaceuticals Inc SUBSTITUTED 1,4-DIHYDRO-4-OXO-1,8-NAPHTHPYRIDINE HETEROCYCLIC ANALOGUES
JP4639149B2 (ja) * 2003-09-10 2011-02-23 杏林製薬株式会社 ７−（４−置換−３−シクロプロピルアミノメチル−１−ピロリジニル）キノロンカルボン酸誘導体
DE10352979A1 (de) * 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
ZA200607248B (en) * 2004-03-15 2009-02-25 Sunesis Pharmaceutical Inc SNS-595 and methods of using the same
AU2013201203C1 (en) * 2004-03-15 2015-04-23 Sumitomo Dainippon Pharma Co., Ltd. Sns-595 and methods of using the same
US7268231B2 (en) * 2004-10-14 2007-09-11 Hoffmann-La Roche Inc. 1,5-Naphthyridine azolinone
KR100890533B1 (ko) * 2004-10-14 2009-03-27 에프. 호프만-라 로슈 아게 Ｃｄｋ1 저해제로서의 퀴나졸리닐메틸렌 티아졸리논
US7563805B2 (en) * 2005-05-19 2009-07-21 Daiichi Pharmaceutical Co., Ltd. Tri-, tetra-substituted-3-aminopyrrolidine derivative
RU2420524C2 (ru) * 2005-05-19 2011-06-10 Дайити Санкио Компани, Лимитед Производные три- или тетра-замещенного-3-аминопирролидина
WO2007022474A2 (en) * 2005-08-19 2007-02-22 Cylene Pharmaceuticals, Inc. HUMAN RIBOSOMAL DNA(rDNA) AND RIBOSOMAL RNA (rRNA) NUCLEIC ACIDS AND USES THEREOF
AU2013219242C1 (en) * 2005-09-02 2016-09-22 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
EP1931339B1 (en) * 2005-09-02 2018-05-16 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
CN104873502A (zh) * 2005-09-02 2015-09-02 逊尼希思制药公司 使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸治疗癌症的方法
KR20140057409A (ko) * 2005-09-02 2014-05-12 선에시스 파마슈티컬스 인코포레이티드 암 치료를 위한 (＋)-1,4-디히드로-7-［(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리디닐］-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카르복실산의 사용 방법
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
RU2428983C2 (ru) * 2005-09-02 2011-09-20 Санесис Фармасьютикалз, Инк. Способы применения (+)-1,4-дигидро-7-[(3s,4s)-3-метокси-4-(метиламино)-1-пирролидинил]-4-оксо-1-(2-тиазолил)-1,8-нафтиридин-3-карбоновой кислоты для лечения рака
CA2622725A1 (en) * 2005-09-14 2007-03-22 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
EP2354138A1 (en) 2006-06-12 2011-08-10 Sunesis Pharmaceuticals, Inc. Compounds and compositions for treatment of cancer
US20100048609A1 (en) * 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
EP3025712A1 (en) * 2006-08-02 2016-06-01 Sunesis Pharmaceuticals, Inc. Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and cytarabine (ara-c) for the treatment of leukemia
CN103720701A (zh) * 2007-10-22 2014-04-16 逊尼希思制药公司 在联合治疗中使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸的方法
AU2008335772B2 (en) * 2007-12-10 2014-11-27 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3- methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1- (2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
NZ593763A (en) 2008-12-31 2013-11-29 Sunesis Pharmaceuticals Inc Method of preparing (+)-1,4-dihydro-7-[(3s,4s)-3methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
SG10201400258SA (en) 2009-02-27 2014-05-29 Sunesis Pharmaceuticals Inc Methods Of Using SNS-595 For Treatment Of Cancer Subjects With Reduced BRCA2 Activity
UA110465C2 (en) * 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
US8470817B2 (en) * 2009-10-26 2013-06-25 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
PL2712358T3 (pl) * 2011-05-13 2017-05-31 Array Biopharma, Inc. Związki mocznika pirolidynowego, tiomocznika pirolidynowego oraz guanidyny pirolidynowej jako inhibitory kinazy trka
CN103497186B (zh) * 2013-09-24 2015-02-25 浙江司太立制药股份有限公司 含有烷氧亚氨基取代的萘啶酮羧酸衍生物及其制备方法
WO2018174266A1 (ja) * 2017-03-24 2018-09-27 湧永製薬株式会社 新規ピリドンカルボン酸誘導体又はその塩

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988463A (en) * 1974-05-06 1976-10-26 Merck & Co., Inc. Method of preventing metastasis of H. Ep. No. 3
US4384001A (en) * 1978-12-21 1983-05-17 Gosalvez Mario Treatment of tumors with thiazolidine-4-carboxylic acid
US4730000A (en) * 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
NZ210847A (en) * 1984-01-26 1988-02-29 Abbott Lab Naphthyridine and pyridopyrimidine derivatives and pharmaceutical compositions
DE3577089D1 (de) * 1984-01-26 1990-05-17 Abbott Lab Antibakterielle chinolinderivate.
JPS61152682A (ja) * 1984-12-27 1986-07-11 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸誘導体、そのエステルおよびその塩
JPS61251667A (ja) * 1985-04-30 1986-11-08 Otsuka Pharmaceut Co Ltd ベンゾヘテロ環化合物
IE60420B1 (en) * 1985-06-13 1994-07-13 Schering Corp Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
EP0226624A1 (en) * 1985-06-14 1987-07-01 The Upjohn Company Cyclopentapyrazole and tetrahydroindazole compounds
JPS6233176A (ja) * 1985-08-05 1987-02-13 Toyama Chem Co Ltd １，４−ジヒドロ−４−オキソナフチリジン誘導体およびその塩
JP2704428B2 (ja) * 1988-06-15 1998-01-26 富山化学工業株式会社 キノロンカルボン酸誘導体またはその塩
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
JPH06233176A (ja) * 1993-01-29 1994-08-19 Sony Corp ビデオカメラ

Also Published As

Publication number Publication date
JP3391796B2 (ja) 2003-03-31
ATE209645T1 (de) 2001-12-15
SI0787726T1 (en) 2002-04-30
SK281341B6 (sk) 2001-02-12
CZ364396A3 (en) 1997-06-11
CA2192824C (en) 2006-11-07
NO307255B1 (no) 2000-03-06
NO965305L (no) 1997-02-04
FI965020A0 (fi) 1996-12-13
DK0787726T3 (da) 2002-02-11
HUT75777A (en) 1997-05-28
RO117793B1 (ro) 2002-07-30
EP0787726B1 (en) 2001-11-28
US5817669A (en) 1998-10-06
AU679859B2 (en) 1997-07-10
KR100350921B1 (ko) 2002-11-18
DE69524251T2 (de) 2002-07-11
HU9603455D0 (en) 1997-02-28
PL317726A1 (en) 1997-04-28
FI965020A7 (fi) 1996-12-16
SK157496A3 (en) 1997-08-06
CN1158614A (zh) 1997-09-03
PT787726E (pt) 2002-04-29
CN1053668C (zh) 2000-06-21
NZ287139A (en) 1997-07-27
BR9508037A (pt) 1997-09-16
EP0787726A4 (instruction) 1997-08-06
ES2163512T3 (es) 2002-02-01
PL181867B1 (pl) 2001-09-28
TW319769B (instruction) 1997-11-11
EP0787726A1 (en) 1997-08-06
MX9606331A (es) 1997-03-29
CA2192824A1 (en) 1995-12-21
HK1000495A1 (en) 2002-07-19
WO1995034559A1 (fr) 1995-12-21
NO965305D0 (no) 1996-12-11
DE69524251D1 (de) 2002-01-10
HU220072B (hu) 2001-10-28
FI112485B (fi) 2003-12-15
RU2151770C1 (ru) 2000-06-27
AU2576795A (en) 1996-01-05

Similar Documents

Publication Publication Date Title
CZ292631B6 (cs) Deriváty pyridonkarboxylové kyseliny, protinádorové a farmakologické prostředky je obsahující
HK1000495B (en) Novel compound, process for producing the same, and antitumor agent
JP4323574B2 (ja) 抗腫瘍剤
CN104854101B (zh) Alk激酶抑制剂
JP3514490B2 (ja) トリフルオロメチルピロロインドールカルボン酸エステル誘導体及びその製造方法
US6316438B1 (en) Fused pyridopyridazine inhibitors of cGMP phosphodiesterase
TW200813020A (en) Substituted 3-amino-pyrrolidino-4-lactams
CN1143080A (zh) 7-二环取代的-3-喹喏酮羧酸衍生物的制备方法
HU194561B (en) Process for preparing novel, aminopyrrolidinyl group-substituted 1,8-naphthyridine derivatives and pharmaceuticals comprising such compounds as active substance
IE63492B1 (en) A Spiro Compound
KR20160034384A (ko) 인돌 및 피롤의 유도체, 이의 제조 방법 및 이를 함유하는 약제 조성물
KR20150138847A (ko) Ｐｅｒｋ 저해제로서의 신규한 ｎ―（２，３―디히드로―１ｈ―피롤로［２，３―ｂ］피리딘―５―일）―４―퀴나졸린아민 및 ｎ―（２，３―디히드로―１ｈ―인돌―５―일）―４―퀴나졸린아민 유도체
JP2948660B2 (ja) 新規なピリドンカルボン酸誘導体
HUT61304A (en) Process for producing azetidinyl-substituted pyridone derivatives and pharmaceutical compositions comprising such compounds
JP5079612B2 (ja) 抗腫瘍剤
WO1995021163A1 (en) Pyridonecarboxylic acid derivative substituted by bicyclic amino group, ester thereof, salt thereof, and bicyclic amine as intermediate therefor
CN108948003B (zh) 作为mTOR抑制剂的吡嗪并[2,3-c]喹啉-2（1H）-酮类化合物的制备及用途
AU2002327182B2 (en) Novel heterocyclic antibacterial compounds
JPH0873460A (ja) １，８−ナフチリジン化合物および抗腫瘍剤
TWI894413B (zh) 作為ｋｒａｓ抑制劑的雜環化合物的製備及其應用方法
KR100332527B1 (ko) 피리돈카르본산유도체또는이것의염및그제조방법
WO1997031919A1 (fr) Derives d'acide pyridonecarboxylique et leur intermediaires de synthese
JPH0834786A (ja) トリフルオロメチルピロロインドール誘導体及びその製造方法
JPH0834787A (ja) ピロロカルバゾール誘導体及びその製造方法
JP2002114785A (ja) １，８−ナフチリジン誘導体および抗腫瘍剤

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic
MK4A Patent expired

Effective date: 20150606